Numerous clinical trials evaluate the therapeutic profile of darolutamide across various oncological conditions, primarily targeting advanced prostate malignancies—including metastatic castration-resistant and metastatic hormone-sensitive prostate cancer—and androgen receptor-positive triple-negative breast carcinoma. Spanning early safety and pharmacokinetic evaluations to confirmatory Phase 3 and Phase 4 protocols, trial recruitment statuses range from completed and active to currently recruiting. These studies are sponsored by leading pharmaceutical entities such as Bayer and Pfizer alongside academic institutions like the Canadian Cancer Trials Group.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06625970 | RECRUITING | High Risk Prostate Carcinoma; Prostate Cancer |
UNICANCER |
2025-04-10 | PHASE3 |
| NCT07190300 | RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Novartis Pharmaceuticals |
2026-01-13 | PHASE1; PHASE2 |
| NCT07730151 | NOT_YET_RECRUITING | Prostate Cancer; Prostate; Prostate Cancer Patients |
RenJi Hospital |
2026-08-01 | PHASE2 |
| NCT07649421 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
West China Hospital |
2026-08-01 | PHASE2 |
| NCT07711002 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
AstraZeneca |
2026-10-01 | PHASE3 |
| NCT05367440 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
AstraZeneca |
2022-06-02 | PHASE1; PHASE2 |
| NCT06592924 | RECRUITING | Prostate Cancer (Adenocarcinoma) |
Canadian Cancer Trials Group |
2025-05-28 | PHASE3 |
| NCT06378866 | RECRUITING | Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma |
Mayo Clinic |
2024-06-03 | PHASE2 |
| NCT05826509 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Institut Claudius Regaud |
2023-08-10 | PHASE2 |
| NCT04070209 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer; Castration-resistant Prostate Cancer |
Sir Mortimer B. Davis - Jewish General Hospital |
2020-10-19 | PHASE2 |
| NCT06282588 | RECRUITING | Prostate Cancer |
Cancer Research Antwerp |
2023-12-13 | PHASE2; PHASE3 |
| NCT07142551 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2026-03-09 | PHASE2 |
| NCT06401980 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Swiss Cancer Institute |
2024-10-22 | PHASE2 |
| NCT07717099 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cance |
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD |
2026-09 | PHASE2 |
| NCT06660862 | NOT_YET_RECRUITING | Prostate Cancer |
University of Chicago |
2026-11 | PHASE4 |
| NCT06276465 | RECRUITING | Prostatic Cancer, Castration-Resistant |
UNICANCER |
2024-10-07 | PHASE3 |
| NCT07751133 | RECRUITING | Prostate Cancer; mHSPC; mCRPC |
University College, London |
2026-08-28 | PHASE3 |
| NCT07611110 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2026-05-04 | PHASE3 |
| NCT07282197 | NOT_YET_RECRUITING | Prostate Cancer |
Peking University First Hospital |
2026-01 | PHASE2 |
| NCT06844383 | RECRUITING | Prostate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer) |
Prostate Cancer Clinical Trials Consortium |
2026-05-04 | PHASE2 |
| NCT05771896 | WITHDRAWN | Metastatic Prostate Cancer |
GenesisCare USA |
2023-09 | PHASE3 |
| NCT04176081 | NOT_YET_RECRUITING | Prostate Cancer |
University Health Network, Toronto |
2024-07-02 | PHASE2 |
| NCT06463457 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Advanced Prostate Cancer; Hormone Sensitive Prostate Cancer |
Atish Choudhury, MD |
2024-12-13 | PHASE2 |
| NCT07450599 | RECRUITING | High-risk Localized Prostate Cancer |
Bayer |
2026-04-27 | PHASE2 |
| NCT07016399 | RECRUITING | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma |
Vandana Abramson |
2025-09-09 | PHASE2 |
| NCT06785636 | RECRUITING | mCRPC (Metastatic Castration-resistant Prostate Cancer); Prostate Cancer |
Pathos AI, Inc. |
2025-02-07 | PHASE1; PHASE2 |
| NCT04464226 | ACTIVE_NOT_RECRUITING | Cancer |
Bayer |
2020-10-20 | PHASE3 |
| NCT07795177 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer |
Anhui Medical University |
2026-10-01 | PHASE2 |
| NCT07140900 | RECRUITING | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) |
Amgen |
2025-10-07 | PHASE1 |
| NCT07723248 | RECRUITING | Metastatic Castration Resistant Prostate Cancer |
ORIC Pharmaceuticals |
2026-08-03 | PHASE3 |
| NCT04916613 | RECRUITING | Prostate Cancer Metastatic |
UNICANCER |
2022-04-19 | PHASE3 |
| NCT07244341 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Daiichi Sankyo |
2025-12-03 | PHASE1 |
| NCT04136353 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
University of Sydney |
2020-03-31 | PHASE3 |
| NCT06190899 | RECRUITING | mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Diseases, Male; Urogenital Diseases, Male; Prostatic Disease; Prostatic Neoplasms, Castration-Resistant; Prostate Cancer |
Celcuity Inc |
2024-01-01 | PHASE1; PHASE2 |
| NCT07476677 | NOT_YET_RECRUITING | Prostate Cancer |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2026-04-01 | PHASE2 |
| NCT07027124 | RECRUITING | Prostate Cancer; High-risk Prostate Cancer |
Icahn School of Medicine at Mount Sinai |
2026-05-21 | PHASE2 |
| NCT07516704 | NOT_YET_RECRUITING | Prostate Cancer |
Zhongda Hospital |
2026-04-01 | EARLY_PHASE1 |
| NCT06220864 | RECRUITING | Advanced Solid Tumor |
Synnovation Therapeutics, Inc. |
2024-02-23 | PHASE1 |
| NCT07503379 | RECRUITING | mHSPC |
Yonghong Li |
2026-04-16 | PHASE2 |
| NCT04025372 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Brigham and Women's Hospital |
2020-06-01 | PHASE2 |
| NCT06120491 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Sensitive Prostate Cancer |
AstraZeneca |
2023-11-21 | PHASE3 |
| NCT07103018 | RECRUITING | Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer Patients; Metastatic Castration-resistant Prostate Cancer, mCRPC; mCRPC; mCRPC (Metastatic Castration-resistant Prostate Cancer) |
K36 Therapeutics, Inc. |
2025-11-21 | PHASE1 |
| NCT05818683 | RECRUITING | Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer |
Janssen Research & Development, LLC |
2023-04-26 | PHASE1 |
| NCT05794906 | ACTIVE_NOT_RECRUITING | Biochemically Recurrent Prostate Cancer |
Bayer |
2023-04-03 | PHASE3 |
| NCT07677566 | NOT_YET_RECRUITING | Prostate Cancer; Prostate Cancer Patients |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2026-07-01 | PHASE4 |
| NCT05519449 | RECRUITING | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer |
Janux Therapeutics |
2022-09-15 | PHASE1 |
| NCT05413421 | RECRUITING | Metastatic Prostate Cancer |
ORIC Pharmaceuticals |
2022-06-01 | PHASE1 |
| NCT07617272 | RECRUITING | Prostate Cancer (Adenocarcinoma) |
Region Stockholm |
2025-11-09 | PHASE2 |
| NCT05762536 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Erasmus Medical Center |
2023-11-29 | PHASE2 |
| NCT05348876 | RECRUITING | Non-metastatic Castration-resistant Prostate Cancer |
Bayer |
2022-08-03 | PHASE4 |
| NCT06594926 | RECRUITING | Prostate Cancer |
Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
2024-08-14 | PHASE2 |
| NCT07620041 | NOT_YET_RECRUITING | Refractory or Relapsed Solid Tumors |
Qilu Pharmaceutical Co., Ltd. |
2026-06-05 | PHASE1 |
| NCT03903835 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Karolinska Institutet |
2019-02-01 | PHASE3 |
| NCT05346848 | RECRUITING | Prostate Cancer |
Institut Bergonié |
2023-02-24 | PHASE2 |
| NCT05669664 | ACTIVE_NOT_RECRUITING | Locally Advanced Salivary Gland Carcinoma; Metastatic Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Unresectable Salivary Gland Carcinoma |
National Cancer Institute (NCI) |
2023-07-20 | PHASE2 |
| NCT05050084 | ACTIVE_NOT_RECRUITING | Prostate Adenocarcinoma |
NRG Oncology |
2021-12-06 | PHASE3 |
| NCT06173362 | RECRUITING | Advanced Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8 |
University of California, Davis |
2023-11-09 | PHASE2 |
| NCT07172685 | RECRUITING | Prostate Cancer |
Qilu Hospital of Shandong University |
2025-07-30 | |
| NCT05938270 | COMPLETED | Prostate Cancer |
AstraZeneca |
2023-09-21 | PHASE1 |
| NCT04484818 | ACTIVE_NOT_RECRUITING | Prostate Carcinoma |
ECOG-ACRIN Cancer Research Group |
2021-03-01 | PHASE3 |
| NCT04319783 | ACTIVE_NOT_RECRUITING | Advanced Prostate Carcinoma; Cancer of Prostate; PSA; Castrate Resistant Prostate Cancer |
Trans Tasman Radiation Oncology Group |
2021-06-02 | PHASE2 |
| NCT06631521 | RECRUITING | Prostate CA; Prostate Cancer (Adenocarcinoma); Prostate Cancer Surgery |
AdventHealth |
2024-10-22 | PHASE1 |
| NCT06568094 | RECRUITING | Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2024-09-25 | PHASE1; PHASE2 |
| NCT06575257 | RECRUITING | Prostate Cancer |
Xijing Hospital |
2024-05-01 | PHASE2 |
| NCT06627530 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Brazilian Clinical Research Institute |
2025-02-17 | PHASE4 |
| NCT04641078 | UNKNOWN | Prostate Cancer; Prostate Cancer Recurrent; Prostate Cancer Metastatic; Metastatic Cancer; Oligometastasis |
University Hospital, Ghent |
2021-02-12 | PHASE2 |
| NCT06169124 | ACTIVE_NOT_RECRUITING | Adult Ovarian Granulosa Cell Tumor |
National Cancer Institute (NCI) |
2024-02-08 | PHASE2 |
| NCT05116475 | RECRUITING | Prostate Cancer |
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie |
2022-08-30 | PHASE3 |
| NCT06177015 | RECRUITING | Metastatic Prostate Cancer; Intermitent Anti-androgen Therapy |
The First Affiliated Hospital with Nanjing Medical University |
2023-12-11 | PHASE3 |
| NCT05683964 | ACTIVE_NOT_RECRUITING | Prostate Adenocarcinoma; Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Beth Israel Deaconess Medical Center |
2023-01-19 | EARLY_PHASE1 |
| NCT04335682 | COMPLETED | Metastatic Prostate Cancer; Prostate Cancer Metastatic; Prostate Cancer; Castrate Resistant Prostate Cancer; Hormone Sensitive Prostate Cancer; Non-metastatic Prostate Cancer |
Alliance Foundation Trials, LLC. |
2021-08-17 | PHASE2 |
| NCT04925648 | COMPLETED | Metastatic Prostate Cancer |
St Vincent's Hospital, Sydney |
2021-10-18 | PHASE2 |
| NCT06029036 | UNKNOWN | Prostate Cancer |
Peking University First Hospital |
2023-08-05 | PHASE2 |
| NCT05617885 | COMPLETED | Metastatic Prostate Cancer; Non-metastatic Prostate Cancer; Prostate Cancer |
Praful Ravi, MB BCHir, MRCP |
2023-08-09 | PHASE1 |
| NCT03568656 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors |
CellCentric Ltd. |
2018-07-23 | PHASE1; PHASE2 |
| NCT05676203 | ACTIVE_NOT_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Jena University Hospital |
2023-05-16 | PHASE3 |
| NCT05059236 | ACTIVE_NOT_RECRUITING | Metastatic Hormone-sensitive Prostate Cancer |
Bayer |
2021-11-04 | PHASE2 |
| NCT05900973 | UNKNOWN | Prostate Cancer |
D'Or Institute for Research and Education |
2023-07-20 | PHASE2 |
| NCT05171387 | COMPLETED | Prostate Cancer |
Bayer |
2021-11-30 | PHASE2 |
| NCT03385655 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Canadian Cancer Trials Group |
2018-08-01 | PHASE2 |
| NCT05526248 | COMPLETED | Biochemically Recurrent Prostate Cancer |
Bayer |
2022-12-19 | PHASE2 |
| NCT05694819 | COMPLETED | Salivary Gland Cancer |
National Cancer Center Hospital East |
2020-04-17 | PHASE2 |
| NCT04736199 | COMPLETED | Prostatic Neoplasms |
Bayer |
2021-02-23 | PHASE3 |
| NCT05999968 | TERMINATED | Prostatic Neoplasms |
Eli Lilly and Company |
2024-01-12 | PHASE1 |
| NCT04558866 | COMPLETED | Prostate Cancer |
Latin American Cooperative Oncology Group |
2021-06-09 | PHASE2 |
| NCT02972060 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-12-01 | PHASE2 |
| NCT05249712 | UNKNOWN | Prostate Cancer |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2022-01-01 | PHASE2 |
| NCT03724747 | COMPLETED | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Bayer |
2018-12-18 | PHASE1 |
| NCT04737109 | TERMINATED | Castrate Resistant Prostate Cancer |
David VanderWeele |
2021-07-13 | PHASE1; PHASE2 |
| NCT04157088 | TERMINATED | Prostatic Cancer, Castration-Resistant |
Bayer |
2019-12-17 | PHASE2 |
| NCT04237584 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
MANA RBM |
2020-06-30 | PHASE3 |
| NCT03314324 | COMPLETED | Metastatic Castrate-resistant Prostate (CRPC) Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2017-11-29 | PHASE2 |
| NCT03383679 | COMPLETED | Breast Cancer Female; Triple Negative and Androgen Receptor Positive |
UNICANCER |
2018-03-14 | PHASE2 |
| NCT02799602 | COMPLETED | Metastatic Hormone-sensitive Prostate Cancer |
Bayer |
2016-11-30 | PHASE3 |
| NCT02933801 | TERMINATED | Prostate Cancer Metastatic; Prostate Cancer |
Swiss Cancer Institute |
2017-03-31 | PHASE2 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT04070209 | Recruiting | Metastatic Prostate Cancer|Castration-resistant Prostate Cancer |
Sir Mortimer B. Davis - Jewish General Hospital |
2020-10-19 | Phase 2 |
| NCT03704519 | COMPLETED | Cerebrovascular Circulation |
Bayer |
2018-10-23 | PHASE1 |
| NCT03004534 | COMPLETED | Breast Cancer Female |
Translational Research in Oncology |
2017-09-05 | EARLY_PHASE1 |
| NCT02200614 | COMPLETED | Prostate Cancer Non-Metastatic; Castration-Resistant |
Bayer |
2014-09-12 | PHASE3 |
| NCT03237416 | COMPLETED | Prostatic Neoplasms |
Bayer |
2017-08-02 | PHASE1 |
| NCT03048110 | COMPLETED | Biological Availability |
Bayer |
2017-02-15 | PHASE1 |
| NCT02894385 | COMPLETED | Pharmacokinetics; Hepatic Insufficiency; Renal Insufficiency |
Bayer |
2016-09-13 | PHASE1 |
| NCT02671097 | COMPLETED | Healthy Volunteers; Pharmacokinetics; Drug Interaction |
Bayer |
2016-02 | PHASE1 |
| NCT02363855 | COMPLETED | Prostatic Neoplasms |
Bayer |
2015-02-23 | PHASE1 |
| NCT01429064 | COMPLETED | Prostate Cancer |
Orion Corporation, Orion Pharma |
2011-06 | PHASE2 |
| NCT02418650 | COMPLETED | Healthy |
Orion Corporation, Orion Pharma |
2015-03 | PHASE1 |
| NCT01784757 | COMPLETED | Prostate Cancer |
Orion Corporation, Orion Pharma |
2013-03 | PHASE1 |
| NCT01317641 | COMPLETED | Prostate Cancer |
Orion Corporation, Orion Pharma |
2011-03 | PHASE1; PHASE2 |
| NCT01317641 | Completed | Prostate Cancer |
Orion Corporation Orion Pharma|Endo Pharmaceuticals |
2011-03 | Phase 1|Phase 2 |
(data from https://clinicaltrials.gov, updated on 2026-07-31)
Check the
ODM-201 (Darolutamide)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- ODM-201 (Darolutamide) Solubility in DMSO
- ODM-201 (Darolutamide) Stock Solution
- ODM-201 (Darolutamide) Storage
- ODM-201 (Darolutamide) Stability
- ODM-201 (Darolutamide) Molecular Weight
- ODM-201 (Darolutamide) SMILES
- ODM-201 (Darolutamide) CAS Number
- ODM-201 (Darolutamide) Chemical Structure (2D and 3D)
- ODM-201 (Darolutamide) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.